Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
C 7.32 -4.44% -0.34
ALIM closed down 4.44 percent on Friday, March 5, 2021, on 75 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical ALIM trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
NR7 Range Contraction -4.44%
Lower Bollinger Band Touch Weakness -4.44%
Fell Below 20 DMA Bearish -10.73%
20 DMA Support Bullish -18.67%
Older End-of-Day Signals for ALIM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Alimera Sciences, Inc. Description

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biopharmaceutical Diseases Eye Organ Systems Disease Diabetes Ophthalmic Macular Degeneration Related Macular Degeneration Retina Diabetic Retinopathy Icos Macular Edema Blindness Vein Age Related Macular Degeneration Diabetic Macular Edema Pivotal Fluid Dynamics Glucocorticoids Corticosteroid Pregnanes Alimera Sciences Diketones Fluocinolone Psivida Retinal Vein Occlusion

Is ALIM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.79
52 Week Low 2.8602
Average Volume 68,927
200-Day Moving Average 5.72
50-Day Moving Average 7.01
20-Day Moving Average 8.45
10-Day Moving Average 8.25
Average True Range 0.83
ADX 34.71
+DI 22.62
-DI 28.14
Chandelier Exit (Long, 3 ATRs ) 8.31
Chandelier Exit (Short, 3 ATRs ) 9.28
Upper Bollinger Band 9.56
Lower Bollinger Band 7.34
Percent B (%b) -0.01
BandWidth 26.21
MACD Line 0.22
MACD Signal Line 0.45
MACD Histogram -0.2344
Fundamentals Value
Market Cap 37.56 Million
Num Shares 5.13 Million
EPS 0.30
Price-to-Earnings (P/E) Ratio 24.16
Price-to-Sales 0.43
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.97
Resistance 3 (R3) 8.98 8.44 8.70
Resistance 2 (R2) 8.44 8.02 8.44 8.60
Resistance 1 (R1) 7.88 7.76 7.61 7.87 8.51
Pivot Point 7.34 7.34 7.21 7.34 7.34
Support 1 (S1) 6.78 6.92 6.51 6.77 6.13
Support 2 (S2) 6.24 6.66 6.24 6.04
Support 3 (S3) 5.68 6.24 5.95
Support 4 (S4) 5.67